Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295503 · ClinicalTrials.gov registry record · Phase 2
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00295503 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 53 participants.
The verdict
NCT00295503, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Interventions
- DRUG cisplatin
- DRUG bevacizumab
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295503
The ClinicalTrials.gov registry entry for NCT00295503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00295503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295503 about?
NCT00295503 is a clinical study titled "Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma". To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
What is the current status of trial NCT00295503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2006-02. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00295503?
The interventions under investigation include: cisplatin (DRUG), bevacizumab (DRUG), pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00295503?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.